Literature DB >> 9813792

Rapid response of emotional incontinence to selective serotonin reuptake inhibitors.

Z Nahas1, K A Arlinghaus, K J Kotrla, R R Clearman, M S George.   

Abstract

Emotional incontinence (EI) is a perturbing condition characterized by uncontrollable outbursts of exaggerated, involuntary facial expressions and pathological crying or laughter. There is increasing evidence that serotonergic neurotransmission may be damaged in EI. The authors report 4 pathological crying cases (3 poststroke and 1 with multiple sclerosis) and 1 case of pathological laughter after traumatic brain injury. EI improved dramatically with three different selective serotonin reuptake inhibitors (fluoxetine, sertraline, and paroxetine) in the context of these different CNS diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813792     DOI: 10.1176/jnp.10.4.453

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  16 in total

Review 1.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Abnormal pontine activation in pathological laughing as shown by functional magnetic resonance imaging.

Authors:  H Kosaka; N Omata; M Omori; T Shimoyama; T Murata; K Kashikura; T Takahashi; J Murayama; Y Yonekura; Y Wada
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12       Impact factor: 10.154

Review 3.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Pathological laughter as onset symptom in atypical parkinsonisms.

Authors:  Anna De Rosa; Sabina Pappatà; Silvio Peluso; Francesco Saccà; Maria Lieto; Alessandro Filla; Giuseppe De Michele
Journal:  J Neurol       Date:  2016-11-24       Impact factor: 4.849

Review 5.  Current concepts in the pharmacotherapy of pseudobulbar affect.

Authors:  Erik P Pioro
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

6.  [Amyotrophic lateral sclerosis: management of bulbar symptoms].

Authors:  P Kraft; M Beck; A Grimm; C Wessig; K Reiners; K V Toyka
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

Review 7.  Common psychiatric syndromes and pharmacologic treatments of traumatic brain injury.

Authors:  L A Labbate; D L Warden
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

8.  The causes and treatment of pseudobulbar affect in ischemic stroke.

Authors:  Preethi Balakrishnan; Howard Rosen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-06

Review 9.  Dextromethorphan/quinidine sulfate for pseudobulbar affect.

Authors:  Howard Rosen
Journal:  Drugs Today (Barc)       Date:  2008-09       Impact factor: 2.245

10.  Altered serotonin, dopamine and norepinepherine levels in 15q duplication and Angelman syndrome mouse models.

Authors:  M Febin Farook; Michael DeCuypere; Keith Hyland; Toru Takumi; Mark S LeDoux; Lawrence T Reiter
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.